Overview
Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp (NASDAQ: ADPT), disclosed a package of sales and option exercises executed from April 17 through April 21, 2026. The filings show total common-stock sales of $1,008,622 and common-stock acquisitions via option exercise valued at $517,879. Rubinstein carried out all reported trades under a Rule 10b5-1 trading plan that she adopted on November 18, 2025.
Transaction detail
Over the three trading days, Rubinstein sold a cumulative 69,061 shares of Adaptive Biotechnologies common stock. The overall weighted average sale prices for those lots ranged from $14.55 to $14.66 per share. The day-by-day breakdown in the disclosures is as follows:
- April 17, 2026 - 19,060 shares sold at a weighted average price of $14.57 per share, with the individual sale prices ranging from $14.38 to $14.91.
- April 20, 2026 - 19,060 shares sold at a weighted average price of $14.55 per share, with individual prices between $14.14 and $14.82.
- April 21, 2026 - 30,941 shares sold at a weighted average price of $14.66 per share, with the range of individual transaction prices from $14.18 to $15.13.
Concurrently, Rubinstein exercised options to acquire 56,047 shares of common stock. The exercise prices on those options ranged from $8.46 to $12.14 per share. The option exercise schedule reported in the filings is described below:
- April 17, 2026 - 14,722 shares acquired at an exercise price of $8.46 per share. Those options reflected a vesting schedule that included 1/4 of the options vesting on March 4, 2024, followed by 1/48 vesting monthly thereafter.
- April 20, 2026 - 14,722 shares acquired at an exercise price of $8.46 per share, from the same vesting schedule.
- April 21, 2026 - 14,722 shares acquired at $8.46 per share, plus an additional 11,881 shares acquired at an exercise price of $12.14 per share. The filings state that the latter options were fully vested and exercisable.
After these reported sales and option exercises, Rubinstein's direct holdings of Adaptive Biotechnologies common stock stand at 395,146 shares.
Market context and valuation notes
The transactions took place while shares of ADPT were trading at $14.21, a price level that the disclosures highlight alongside the stock's volatility. According to data cited in the filings, Adaptive Biotechnologies has returned 108% over the past year, but the shares have retreated 12.5% year-to-date from a 52-week high of $20.76. The company has a market capitalization reported at $2.19 billion.
InvestingPro analysis referenced in the disclosures indicates the stock appears overvalued relative to its Fair Value estimate. The same commentary notes that price movements in the stock are quite volatile. Investors interested in additional valuation context are pointed to Pro Research Reports and related tools covering more than 1,400 U.S. equities on the InvestingPro platform.
Analyst outlook
Analysts cited in the disclosure maintain price targets on ADPT between $19 and $22, implying what the filings characterize as roughly 44% potential upside from current trading levels.
Related company results disclosed
The filing package also summarizes recent quarterly results for Adeptus Biotechnologies for the fourth quarter of 2025. Those results exceeded analyst expectations, with reported earnings per share of -$0.09 versus a forecast of -$0.18, and revenue of $71.7 million compared with anticipated revenue of $59.33 million, representing a 20.85% beat on the revenue line.
Following those fourth-quarter results, the disclosures note a series of analyst price target changes and reiterations: TD Cowen raised its price target for Adeptus Biotechnologies to $21 from $20 while maintaining its stock rating; BTIG raised its price target to $22 and cited a 54% year-over-year expansion in the company’s core Minimal Residual Disease business for the fourth quarter and a 46% increase for the full year; Piper Sandler reiterated an Overweight rating and projected more than 30% growth in clonoSEQ volumes, while highlighting expanding margins and reimbursement tailwinds.
Takeaways
The filings record a coordinated set of sales and option exercises by a senior operating officer under a pre-established Rule 10b5-1 plan. The disclosures provide precise share counts, exercise prices, vesting schedules, and the dates of each transaction. They also place those moves inside a market backdrop characterized by substantial trailing returns and meaningful volatility, alongside analyst price-target ranges and recent company financial results disclosed for the fourth quarter of 2025.
Note: The information above is taken from regulatory filings and the data cited within them.